Enzo Biochem Announces New York State Health Department Approval of New Women’s Health Diagnostics

NEW YORK–(BUSINESS WIRE)– Enzo Biochem, Inc. (NYSE:ENZ) today announced that the New York State
Department of Health has granted conditional approval for three
additional women’s health related molecular diagnostic tests for use
with the Company’s versatile and economic AmpiProbe® platform. Approval
was given for a real-time PCR-based method for qualitative detection of Neisseria
gonorrhoeae, Chlamydia trachomatis and Trichomonas
vaginalis in vaginal swab specimens.

Elazar Rabbani, Ph.D., Enzo CEO and Chairman, commented “The approval of
these diagnostic tests adds to the Company’s growing panel of women’s
health diagnostics. Additionally, gonorrhoeae, though one with the
highest incidence among women’s sexually transmitted diseases, tends
also to be broadly prevalent among men.

“Since the inception of Enzo, we have been committed to advancing
healthcare and in today’s challenging environment, providing affordable,
reliable diagnostic testing is an imperative. These tests are part of a
continued flow of robust products and services to be released. The
Company’s AmpiProbe®-based pipeline includes an extensive line of assays
for identification of additional women’s health infectious diseases as
well as for the quantification of viral load in serum or plasma
specimens. This proprietary technology platform is the foundation for
this ever increasing line of medically relevant, cost-effective and
easily adaptable solutions for clinical laboratories. The Company’s
unique integrated Life Science-Clinical Lab structure is especially
instrumental in its ability to seamlessly develop and advance products
from innovation through validation and commercialization,” he added.

In addition to these products, Enzo’s development program includes a
line of assays based on its proprietary flow cytometry platform for such
diverse applications as cancer, infectious disease and immunology, to
name a few. The Company also is developing a line of products designed
to aid pathologists in differentiating the characteristics of various
tumors from biopsy specimens. Enzo molecular-based products are targeted
at a market currently estimated to be in excess of $3 billion worth of
laboratory service revenue domestically.

About
Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and intellectual
property through the development of unique diagnostic platform
technologies that provide numerous advantages over previous standards. A
global company, Enzo Biochem utilizes cross-functional teams to develop
and deploy products systems and services that meet the ever-changing and
rapidly growing needs of health care today and into the future.
Underpinning Enzo Biochem’s products and technologies is a broad and
deep intellectual property portfolio, with patent coverage across a
number of key enabling technologies.

Except for historical information, the matters discussed in this news
release may be considered « forward-looking » statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management, including those related
to cash flow, gross margins, revenues, and expenses are dependent on a
number of factors outside of the control of the Company including, inter
alia, the markets for the Company’s products and services, costs of
goods and services, other expenses, government regulations, litigations,
and general business conditions. See Risk Factors in the Company’s Form
10-K for the fiscal year ended July 31, 2016. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that could
materially affect actual results. The Company disclaims any obligations
to update any forward-looking statement as a result of developments
occurring after the date of this press release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170608006284/en/